A Phase 2 interventional study of Ceralasertib in Advanced Solid Tumours, sponsored by AstraZeneca. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
Current module of the study will consist of 2 cohorts as follows:
Cohort A (Advanced Solid Tumours [AST]): A total of \~25 molecularly eligible and centrally confirmed participants dosed at ceralasertib 160 mg twice daily will be enrolled into this cohort.
Cohort B (Metastatic castration-resistant prostate cancer [mCRPC]): A total of \~27 molecularly eligible and centrally confirmed participants dosed at ceralasertib 160 mg twice daily will be enrolled into Cohort B. Unfavourable circulating tumour cells (CTC) count requirement may be introduced for all participants to ensure an adequate (approximately ≥ 50%) number of participants with CTC count ≥ 5/7.5 mL blood.
The screening will have 2 parts, Part 1 and Part 2, which apply for both Cohort A and Cohort B.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following cardiac diseases currently or within the last 6 months:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
Drug: Ceralasertib
Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
Drug: Ceralasertib
Tablets will be administered orally
Also known as: AZD6738
Cohort A (aST): Objective Response Rate (ORR).
ORR is defined as the percentage of participants who have at least one response of complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by response evaluation criteria in solid tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as \>= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
Time frame: 2 years 4 months
Cohort B (mCRPC): Composite Response Rate.
Composite response rate is defined as the investigator assessed radiological response by RECIST 1.1 for soft tissue and visceral lesions and Prostate Cancer Working Group 3 (PCWG3) for bone lesions, confirmed prostate specific antigen (PSA) decline of more than 50%, and/or confirmed circulating tumour cell \[CTC\] conversion from unfavorable (\>=5 cells/7.5 ml blood) to favorable (\<5 cells). Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
Time frame: Up to 2 years 4 months
Cohort A (aST): Duration of Radiological Response (DoR)
DoR is defined as the time from the date of first documented response (confirmed CR/PR) until date of documented progression or death in the absence of disease progression.
Time frame: Up to 2 years 4 months
Cohort A (aST): Progression Free Survival (PFS)
PFS is defined as the time from start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression. Progression is defined using (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
Time frame: Up to 2 years 4 months
Cohort A (aST): Percentage Change in Tumor Size
Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size.
Time frame: Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32), 5 (Week 40), 6 (Week (48), 7 (Week 56)
Cohort B (mRCPC): Percentage Change in Tumor Size
Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
Time frame: Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32)
Cohort A (aST) and B (mCRPC): Number of Participants With Serious and Non-serious Adverse Events
The adverse events as a variable of safety and tolerability after admiration of ceralasertib was determined.
Time frame: From Screening (Day -28 to Day -1) Until Follow-up (30 days post last dose), up to 2 years 4 months
Participants were enrolled in this study from 01 December 2020 to 04 April 2023 at 18 centers in 3 countries.
| Milestone | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|---|---|---|
| Started | 8 | 30 | 1 | 15 |
| Completed | 8 | 27 | 1 | 15 |
| Not completed | 0 | 3 | 0 | 0 |
| Withdrew: Ongoing treatment at data cut off | 0 | 3 | 0 | 0 |
ORR is defined as the percentage of participants who have at least one response of complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by response evaluation criteria in solid tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as \>= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
| Percentage of participants | Cohort A (aST): 160 mg of Ceralasertib |
|---|---|
| Cohort A (aST): Objective Response Rate (ORR). | 7.14 (1.9 to 17.9) |
Composite response rate is defined as the investigator assessed radiological response by RECIST 1.1 for soft tissue and visceral lesions and Prostate Cancer Working Group 3 (PCWG3) for bone lesions, confirmed prostate specific antigen (PSA) decline of more than 50%, and/or confirmed circulating tumour cell \[CTC\] conversion from unfavorable (\>=5 cells/7.5 ml blood) to favorable (\<5 cells). Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
| Percentage of participants | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|
| Cohort B (mCRPC): Composite Response Rate. | 7.7 (0.8 to 26.8) |
DoR is defined as the time from the date of first documented response (confirmed CR/PR) until date of documented progression or death in the absence of disease progression.
No measurements were reported for this outcome.
PFS is defined as the time from start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression. Progression is defined using (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
| Months | Cohort A (aST): 160 mg of Ceralasertib |
|---|---|
| Cohort A (aST): Progression Free Survival (PFS) | 3.7 (1.9 to 5.6) |
Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size.
| Percentage change | Cohort A (aST): 160 mg of Ceralasertib | Cohort A (aST): 240 mg of Ceralasertib |
|---|---|---|
| Scan Visit 1 (Week 8) | 6.6 ± 22.45 | 6.2 ± 10.99 |
| Scan Visit 2 (Week 16) | -4.7 ± 16.83 | 5.4 ± NA |
| Scan Visit 3 (Week 24) | -12.8 ± 21.47 | — |
| Scan Visit 4 (Week 32) | -17.9 ± 34.41 | — |
| Scan Visit 5 (Week 40) | -1.1 ± NA | — |
| Scan Visit 6 (Week 48) | -100 ± NA | — |
| Scan Visit 7 (Week 56) | -100 ± NA | — |
Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.
| Percentage change | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|
| Scan Visit 1 (Week 8) | 2.0 ± 21.35 |
| Scan Visit 2 (Week 16) | -6.0 ± 9.37 |
| Scan Visit 3 (Week 24) | -1.4 ± 11.75 |
| Scan Visit 4 (Week 32) | -5.2 ± 13.21 |
The adverse events as a variable of safety and tolerability after admiration of ceralasertib was determined.
| Participants | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|---|---|---|
| All Adverse events (AE) | 8 | 30 | 1 | 15 |
| Any AE possibly related to treatment | 8 | 21 | 1 | 13 |
| Any AE of CTCAE Grade 3 or higher | 6 | 15 | 1 | 8 |
| Any AE of CTCAE Grade 3 or higher, possibly related to IP | 4 | 6 | 1 | 5 |
| Any AE with outcome of death | 0 | 0 | 1 | 0 |
| Any AE with outcome = death, possibly related to IP | 0 | 0 | 1 | 0 |
| Any SAE (including events with outcome = death) | 6 | 4 | 1 | 4 |
| Any SAE (including events with outcome = death), possibly related to IP | 3 | 2 | 1 | 1 |
| Any SAE leading to discontinuation of IP | 0 | 1 | 1 | 0 |
| Any SAE leading to discontinuation of IP, possibly related to IP | 0 | 0 | 1 | 0 |
| Any AE leading to discontinuation of IP | 0 | 1 | 1 | 1 |
| Any AE leading to discontinuation of IP, possibly related to IP | 0 | 0 | 1 | 1 |
| Any AE leading to dose modification | 4 | 10 | 1 | 5 |
| Any AE leading to dose reduction | 1 | 4 | 0 | 3 |
| Any AE leading to dose interruption | 4 | 7 | 1 | 3 |
| Any AE leading to dosing cycle delays | 1 | 0 | 0 | 1 |
| Any other significant AEs | 0 | 0 | 0 | 0 |
Collected over From Screening (Day -28 to Day -1) Until Follow-up (30 days post last dose), up to 2 years 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (aST): 240 mg of Ceralasertib | 0/8 (0%) | 6/8 (75%) | 8/8 (100%) |
| Cohort A (aST): 160 mg of Ceralasertib | 0/30 (0%) | 4/30 (13.3%) | 30/30 (100%) |
| Cohort B (mCRPC): 240 mg of Ceralasertib | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Cohort B (mCRPC): 160 mg of Ceralasertib | 0/15 (0%) | 4/15 (26.7%) | 15/15 (100%) |
| Event | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/8 | 0/30 | 1/1 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/30 | 1/1 | 0/15 |
| Platelet count decreasedInvestigations | 2/8 | 0/30 | 0/1 | 0/15 |
| SepsisInfections and infestations | 1/8 | 0/30 | 0/1 | 0/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/8 | 0/30 | 0/1 | 0/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/8 | 0/30 | 0/1 | 0/15 |
| Confusional statePsychiatric disorders | 1/8 | 0/30 | 0/1 | 0/15 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/8 | 0/30 | 0/1 | 0/15 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/8 | 0/30 | 0/1 | 0/15 |
| Small intestinal obstructionGastrointestinal disorders | 1/8 | 0/30 | 0/1 | 0/15 |
| Event | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/8 | 0/30 | 1/1 | 1/15 |
| NeutropeniaBlood and lymphatic system disorders | 0/8 | 0/30 | 1/1 | 2/15 |
| Decreased appetiteMetabolism and nutrition disorders | 2/8 | 6/30 | 1/1 | 3/15 |
| DehydrationMetabolism and nutrition disorders | 1/8 | 1/30 | 1/1 | 0/15 |
| AnxietyPsychiatric disorders | 1/8 | 1/30 | 1/1 | 0/15 |
| DepressionPsychiatric disorders | 0/8 | 0/30 | 1/1 | 0/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/8 | 3/30 | 1/1 | 0/15 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/8 | 4/30 | 1/1 | 2/15 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 5/30 | 1/1 | 0/15 |
| Platelet count decreasedInvestigations | 2/8 | 2/30 | 1/1 | 1/15 |
Safety analysis set consists of all participants who received at least 1 dose of study intervention.
| Age, Customized(Participants) | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib | Total |
|---|---|---|---|---|---|
| 18-64 years | 3 | 11 | 0 | 3 | 17 |
| 65-84 years | 5 | 19 | 1 | 12 | 37 |
| ≥ 85 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib | Total |
|---|---|---|---|---|---|
| Female | 5 | 14 | 0 | 0 | 19 |
| Male | 3 | 16 | 1 | 15 | 35 |
| Race/Ethnicity, Customized(Participants) | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib | Total |
|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiin or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 8 | 11 | 0 | 6 | 25 |
| Not Reported | 0 | 7 | 0 | 4 | 11 |
| Missing | 0 | 9 | 0 | 5 | 14 |
| Other | 0 | 3 | 1 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 0 | 1 | 4 |
| Not Hispanic or Latino | 8 | 13 | 1 | 9 | 31 |
| Missing | 0 | 14 | 0 | 5 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the requests portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2020 to primary completion in Feb 2025, 50 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceralasertib
Hereditary Sensory and Autonomic Neuropathies